328 related articles for article (PubMed ID: 17204710)
1. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.
Konijnenberg M; Melis M; Valkema R; Krenning E; de Jong M
J Nucl Med; 2007 Jan; 48(1):134-42. PubMed ID: 17204710
[TBL] [Abstract][Full Text] [Related]
2. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
3. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.
De Jong M; Valkema R; Van Gameren A; Van Boven H; Bex A; Van De Weyer EP; Burggraaf JD; Körner M; Reubi JC; Krenning EP
J Nucl Med; 2004 Jul; 45(7):1168-71. PubMed ID: 15235063
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
5. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
6. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
7. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
8. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
9. Effect of image registration on 3D absorbed dose calculations in
Grassi E; Fioroni F; Berenato S; Patterson N; Ferri V; Braglia L; Filice A; Versari A; Iori M; Spezi E
Phys Med; 2018 Jan; 45():177-185. PubMed ID: 29472084
[TBL] [Abstract][Full Text] [Related]
10. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.
Gustafsson J; Brolin G; Cox M; Ljungberg M; Johansson L; Gleisner KS
Phys Med Biol; 2015 Nov; 60(21):8329-46. PubMed ID: 26458139
[TBL] [Abstract][Full Text] [Related]
12. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney.
Bouchet LG; Bolch WE; Blanco HP; Wessels BW; Siegel JA; Rajon DA; Clairand I; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1113-47. PubMed ID: 12843230
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
Gleisner KS; Brolin G; Sundlöv A; Mjekiqi E; Östlund K; Tennvall J; Larsson E
J Nucl Med; 2015 Jul; 56(7):976-84. PubMed ID: 25999429
[TBL] [Abstract][Full Text] [Related]
14. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
[TBL] [Abstract][Full Text] [Related]
16. Fast beta-emitter Monte Carlo simulations and full patient dose calculations of targeted radionuclide therapy: introducing egs_mird.
Martinov MP; Opara C; Thomson RM; Lee TY
Med Phys; 2022 Sep; 49(9):6137-6149. PubMed ID: 35650012
[TBL] [Abstract][Full Text] [Related]
17. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.
Svensson J; Mölne J; Forssell-Aronsson E; Konijnenberg M; Bernhardt P
Nucl Med Biol; 2012 Aug; 39(6):756-62. PubMed ID: 22445743
[TBL] [Abstract][Full Text] [Related]
19. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
